[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prediabetes-insulin-resistance-impaired-glucose-tolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prediabetes-insulin-resistance-impaired-glucose-tolerance":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,60,104,133,163,214,238,272,317,352,378,403],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053983","risk-informed-shared-decision-making-engagement-strategy-for-patients-with-prediabetes-100053983",false,"NCT07553325","Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes","Pilot Trial of a Risk-informed Shared-decision Engagement Strategy","RISE","Inclusion Criteria:\n\n* prediabetes based on most recent HbA1c (5.7-6.4%) or fasting plasma glucose (100-125 mg\u002FdL) in prior 12 months\n* active patient portal account (MyChart)\n* patient receiving primary care at Johns Hopkins Community Physicians in Frederick\n* have overweight or obesity (BMI ≥ 25 kg\u002Fm2)\n\nExclusion Criteria:\n\n* have diabetes (HbA1c \\> 6.4% in prior 6 months or on diabetes registry)\n* have dementia\n* previously participated in the Diabetes Prevention Program (DPP)","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if knowing risk for diabetes can help adult patients with prediabetes take steps to get care and prevent diabetes. The main questions it aims to answer are:\n\n* Does a shared-decision making visit with a health care team member to talk about the participant's diabetes risk increase participants' taking steps to prevent diabetes?\n* Does a simple message in the patient portal about the participant's diabetes risk increase participants' taking steps to prevent diabetes?\n\nResearchers will compare the visit with usual care at the clinic to see if the visit increases participants' taking steps to prevent diabetes. Separately, the researchers will compare the patient message with usual care at the clinic to see if the message increases participants' taking steps to prevent diabetes.\n\nParticipants will:\n\n* Complete surveys at the beginning of the study and up to 2 additional surveys\n* If the participant falls into the shared decision-making group, the participant will have one 30-minute visit with a healthcare team member to talk about risk of diabetes and how to lower it.",[28,29],"Prediabetes","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)",[31,32,33],"shared decision-making","diabetes risk","diabetes prevention","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-08-01",{"date":42,"type":22},"2028-04-01",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":26,"conditions":51,"keywords":52,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":46},"100635487",{"count":21,"type":22},[25],[28,29],[31,32,33],"2026-06-04",{"date":55,"type":38},"2026-06-08",{"date":57,"type":22},"2026-07-01",{"date":42,"type":22},{"name":44,"class":45},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100640704","food-i-sense-analytics-integrating-ai-into-continuous-glucose-monitoring-data-analysis-for-precision-nutrition-100640704","NCT07626658","Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.","Food_i Sense Analytics: Integrando la Inteligencia Artificial Con la monitorización Continua de la Glucosa Para la nutrición de precisión","Food_i Sense","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Willing and able to undergo 14 days of continuous glucose monitoring (CGM) using a wearable sensor.\n* Able to maintain stable dietary habits during the monitoring period.\n* Able and willing to complete dietary records, including two structured 3-day food logs.\n* Able and willing to photograph all meals during the 14-day monitoring period following instructions provided.\n* Able to keep a record of physical activity as instructed.\n* No previous diagnosis of diabetes or other serious metabolic disorders.\n* Sufficient commitment and availability to attend all study visits (screening, baseline evaluation, final evaluation).\n* Capable of providing written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed diabetes mellitus or other serious metabolic disorders.\n* History of severe gastrointestinal, cardiovascular, or other medical conditions that may interfere with stable diet or physical activity during the study.\n* Pregnant or breastfeeding women.\n* Inability or unwillingness to comply with continuous glucose monitoring (CGM) procedures for 14 days.\n* Participants with skin conditions or allergies that prevent safe use of a CGM sensor.\n* Current participation in another clinical trial that could affect study results.\n* Use of medications that significantly alter glucose metabolism or interfere with CGM accuracy.\n* Inability to attend all scheduled study visits or complete required records (diet logs, photos, questionnaires).\n* Any condition judged by the investigators to make the participant unsuitable for the study or unable to provide informed consent.",true,"70 Years",{"count":71,"type":22},471,"OBSERVATIONAL","This study aims to improve how we understand and manage blood sugar responses in adults without diabetes. Even in people who appear healthy, blood sugar levels after meals can behave in different ways. These patterns may help predict future risk of diseases such as type 2 diabetes or other cardiometabolic problems.\n\nTo study this, researchers at IMDEA Nutrition have developed a computer algorithm called GLIA, which uses artificial intelligence (AI) to analyze continuous glucose monitoring (CGM) data. The goal is to classify people into different \"glucotypes\", meaning typical patterns of how their blood sugar behaves throughout the day. These glucotypes could help tailor dietary recommendations in the future.\n\nGoals of the study\n\n1. Train and validate the GLIA algorithm\\*\\* in a large and diverse sample of adults.\n2. Study how glucotypes relate to health indicators\\*\\*, such as blood pressure, body composition, cholesterol, or lifestyle.\n3. Predict how each person responds to different foods\\*\\*, to support personalized nutrition advice.\n\nWho can participate?\n\nAdults 18-70 years old who:\n\n* Do not\\*have diagnosed diabetes or serious metabolic disease.\n* Agree to wear a glucose sensor for 14 days.\n* Can keep stable eating habits and record diet and physical activity.\n\nWhat participation involves\n\nThe study lasts 3 weeks and includes 3 visits:\n\nVisit 1 - Screening (20 min):\n\n* Review of eligibility criteria.\n* Explanation of the study.\n* Signing informed consent.\n* Visit 2 - Initial assessment (45 min)\n* Collection of personal and health information.\n* Measurements: weight, height, waist, body composition, blood pressure.\n* Placement of a FreeStyle Libre 3 CGM sensor.\n* Instructions for:\n* Completing two 3-day food records (one each week).\n* Taking photos of all meals.\n* Reporting physical activity.\n\nContinuous monitoring (14 days)\n\nVisit 3 - Final evaluation (45 min)\n\n* Review of diet records.\n* Repeat measurements.\n* Blood and urine samples are collected for metabolic and molecular analyses.\n\nMeal photos are analyzed using an AI-based food recognition model. The system identifies foods and estimates nutrients (macronutrients, vitamins, minerals, glycemic index, etc.). This helps researchers understand how meals relate to blood sugar patterns.\n\nPotential benefits: Although participants may not receive direct health benefits, the study will:\n\n* Improve understanding of how healthy people process glucose.\n* Help identify early risk markers for metabolic diseases.\n* Contribute to developing \\*\\*personalized nutrition tools\\*\\* based on individual glucose responses.\n\nRisks: are minimal and mainly include:\n\n* Mild skin irritation from the CGM sensor.\n* Temporary discomfort from blood draw.",[29,75],"Artificial Intelligence Mobile Application",[77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"Continuous glucose monitoring (CGM)","Glucose dynamics","Glucose phenotyping","Glucotypes","Artificial intelligence","Nutrition","Machine-learning","Glucose patterns","Precision nutrition","Chrononutrition","Glycemic variability","Nutritional pattern","Glycemic response modeling","Personalized dietary recommendations","Multimodal metabolic phenotyping","Wearable glucose sensors","AI-driven health monitoring","Cardiometabolic health","Adults Without Diabetes","2026-06-02",{"date":53,"type":38},{"date":99,"type":22},"2026-07",{"date":101,"type":22},"2028-12",{"name":103,"class":45},"IMDEA Food",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":69,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100639574","personalized-meal-timing-and-walking-based-on-glucose-patterns-in-adults-with-prediabetes-100639574","NCT07618663","Personalized Meal Timing and Walking Based on Glucose Patterns in Adults With Prediabetes","CGM-Phenotyped Circadian Glycemic Vulnerability Windows to Personalize Meal Timing and Postprandial Activity in Prediabetes : A Randomized Controlled Trial","CLOCK-PRIME","Inclusion Criteria:\n\n* Age 30 to 70 years\n* Prediabetes, defined as either:\n* HbA1c 5.7% to 6.4% within 3 months of screening, or\n* Fasting plasma glucose 100 to 125 mg\u002FdL on two separate occasions\n* Body mass index 23 to 40 kg\u002Fm²\n* Owns a smartphone compatible with study applications\n* Willing to wear a continuous glucose monitor and wrist activity monitor during the study period\n* Willing to record meals using timestamped meal-photo logging\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current or prior diagnosis of type 1 diabetes or type 2 diabetes\n* Use of glucose-lowering medication within the past 3 months\n* Use of systemic corticosteroid medication within the past 3 months\n* Use of prescription weight-loss medication within the past 3 months\n* Current shift work\n* Transmeridian travel across more than 2 time zones within 4 weeks before enrollment\n* Known untreated or unstable sleep disorder, including obstructive sleep apnea, narcolepsy, or insomnia disorder\n* Pregnancy, planned pregnancy, or breastfeeding\n* Gastrointestinal disease or surgery likely to affect nutrient absorption\n* Current participation in a structured dietary or exercise intervention program\n* Estimated glomerular filtration rate less than 60 mL\u002Fmin\u002F1.73 m²\n* Inability or unwillingness to comply with continuous glucose monitoring, wrist actigraphy, meal logging, or study visits","30 Years",{"count":114,"type":22},105,[25],"This study will test whether glucose sensor data can be used to identify the time of day when adults with prediabetes are most likely to have high blood sugar after meals. Participants will first wear a continuous glucose monitor and wrist activity monitor and record meal times for 10 days. These data will be used to classify each participant's personal \"glycemic vulnerability window,\" such as morning, evening, or generally variable patterns.\n\nParticipants will then be randomly assigned to either personalized meal timing plus a short walk after their most vulnerable meal, or to an attention-matched control group receiving sleep hygiene and general step-count advice. The main outcome will be the change in post-meal glucose exposure during each participant's vulnerable window after 4 weeks.",[28,29,118],"Prediabetes or Diabetes",[28,120,121,122,123],"Continuous Glucose Monitoring","Precision Lifestyle Medicine","Meal Timing","Glycemic Variability","RECRUITING","2026-05-24",{"date":127,"type":38},"2026-06-01",{"date":127,"type":22},{"date":130,"type":22},"2026-07-15",{"name":132,"class":45},"Shifa International Hospital",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":68,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100638562","eating-almonds-before-a-meal-to-control-blood-sugar-100638562","NCT07603739","Eating Almonds Before a Meal to Control Blood Sugar","Interindividual Variability in the Effect of Premeal Almond Supplementation on Glycemic Control - a Double Crossover Study","NUTS","Inclusion Criteria:\n\n* Adults aged 25-50 years\n* Females over 40 years must have had a cycle in the last 6 months\n* Body mass index (BMI) at least 18.5 and at most 55.0 kg\u002Fm2\n* Impaired blood glucose by at least one of the following criteria:\n* Fasting blood glucose at least 100 mg\u002FdL (5.6 mmol\u002FL) and less than 125 mg\u002FdL (6.9 mmol\u002FL)\n* HbA1c at least 5.7% and less than 6.5%\n* Willing and able to comply with study foods\n* Willing and able to ingest acetaminophen as part of study procedures\n* Able to read, speak, and understand English\n\nExclusion Criteria:\n\n* Weight change ≥5% in past 6 months, actively trying to lose weight, or unwilling to remain weight stable throughout the study based on self-report\n* Recent history within past 12 months of medical provider-diagnosed cardiovascular, renal, or liver disease that required treatment\n* Current or past diagnosis of cancer (except skin cancer) in the last 5 years\n* Current or past diagnosis of type 1 or type 2 diabetes\n* Recent history within past 12 months of medical provider-diagnosed gastrointestinal or neurological disorders if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Recent history within past 12 months of medical provider-diagnosed psychiatric disorders including eating disorders or severe depression if not managed\u002Fstable for at least 3 months (with or without treatment)\n* Food allergies or other reasons preventing consumption of study foods\n* Any glucose-lowering medication except biguanides (e.g., Metformin) if stable for at least 3 months or incretins (i.e., GLP-1RA-based) if stable for at least 3 months\n* Current smoking or vaping or history of smoking or vaping in the past 6 months\n* Binge and\u002For heavy drinking (i.e., \\>3 drinks on any given occasion and\u002For \\>7 drinks\u002Fweek)\n* Currently pregnant or planning to become pregnant or breastfeed in the next 3 months by self-report","25 Years","50 Years",{"count":144,"type":22},25,[25],"The goal of this study is to learn whether eating a small serving of almonds before meals can improve blood sugar control in adults who have early signs of problems with blood sugar regulation. The main questions it aims to answer are:\n\n1. Does eating almonds before a meal reduce the rise in blood sugar after eating?\n2. Do some people consistently benefit more than others from eating almonds before meals?",[148,29,149,82],"Glucose Control","Precision Medicine",[82,149,151,148,152,153,28],"Precision Nutrition","Impaired Glucose Tolerance","Insulin Resistance","2026-05-16",{"date":156,"type":38},"2026-05-22",{"date":158,"type":22},"2026-06",{"date":160,"type":22},"2028-07",{"name":162,"class":45},"Pennington Biomedical Research Center",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":68,"sex":17,"minAge":171,"maxAge":69,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":46},"100638542","phase-2-effects-of-different-fish-oil-types-on-type-2-diabetes-risk-factors-in-high-risk-adults-100638542","NCT07575438","Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults","Role of EPA and DHA as Tailored Therapy for People Living With Obesity and High-risk for Type 2 Diabetes (END-T2D): a Randomized Controlled Trial","END-T2D","Inclusion Criteria:\n\nMales and post-menopausal females:\n\n* With a body mass index (BMI \\>25-40 kg\u002Fm2)\n* Having confirmed menopausal status (FSH ≥ 30 U\u002Fl)\n* Non-smokers (tobacco) or have quitted for over a year\n* Low-moderate alcohol consumption: \\\u003C7 alcoholic servings\u002F week\n* Plasma apoB ≥1.05 g\u002FL\n\nExclusion Criteria:\n\n* Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score)\n* Prior history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, angina, heart failure, arrhythmias, flutter, atrial …)\n* Systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg\n* Diabetes or HbA1c ≥ 6.5%\n* Reactive hypoglycaemia\n* Prior history of cancer within the last 3 years or if lymph nodes were removed\n* Thyroid disease - untreated or unstable Synthroid dose\n* Severe renal dysfunction - eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* Hepatic dysfunction - AST\u002FALT \\> 3 times normal limit\n* Anemia - Hb \\\u003C 120 g\u002FL in females and \\\u003C 130 in males\n* Bleeding disorders\n* Blood coagulation problems (i.e. bleeding predisposition)\n* Malabsorptive disease or surgeries (e.g. bariatric surgeries)\n* Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus).\n* Chronic diarrhea\n* Cholecystectomy (e.g. removal of gall bladder)\n* Sleep apnea\n* Seizures\n* Known history of difficulties accessing a vein\n* Known history of vagal shock or loss of consciousness during blood withdrawal\n* Concomitant medications (systemic corticosteroids; hypertension medication; anti-psychotic medications - psycho-active medication that promote weight gain; anticoagulant or anti-aggregates treatment (e.g. aspirin, NSAIDs, warfarin, coumadin..); systemic adrenergic agonists; weight-loss medication (e.g. GLP-1 agonists); lipid lowering medication (e.g. statins, anti-PCSK9); )\n* Allergy to seafood\u002Ffish or corn oil\n* Allergy to bovine gelatine or glycerine (softgel components)\n* Allergy to Xylocaine (anesthesia used during fat tissue biopsy)\n* Anticipated surgery or blood transfusion\n* Known substance abuse\n* Very high physical activity (\\> 5 hours of aerobic exercise per week)\n* Already taking more than 1 gm of EPA and\u002For DHA supplementation per day\n* Lack of compliance to the study requirements (i.e. not being fasting)\n* Cancellation of the same scheduled testing visit more than once\n* Lack of time to participate in the full length of the study (18-22 weeks)\n* Other conditions deemed inappropriate by the study physician (e.g. difficulties in understanding\u002Fcommunicating in French or English)","40 Years",{"count":173,"type":22},84,[175],"PHASE2","The purpose of this clinical trial is to find out whether one type of fish oil works better than another at improving metabolic health in people who are at high risk of developing type 2 diabetes.\n\nSome metabolic problems-such as difficulty controlling blood sugar, unhealthy particles that transport cholesterol in the blood, and poor fat tissue function-can increase the risk of type 2 diabetes. This study aims to determine whether different types of fish oil can:\n\n1. Improve how well the body produces insulin and responds to it,\n2. Improve the quality of the particles that carry \"bad\" cholesterol in the blood, and 3) Improve the health and function of participants' fat tissue.\n\nTo answer these questions, researchers will compare the effects of two types of fish oil: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). These will be compared with corn oil, which is used as a placebo and does not contain EPA or DHA.\n\nWhen included in this study, participants will:\n\nA) Take softgel capsules containing EPA, DHA, or placebo (corn oil) every day for 12 weeks, B) Keep a daily log to record when they take their study softgels, and C) Visit the research unit six times, including one and a half days before and after the intervention, to complete specialized metabolic tests that are mostly only available in research settings.",[178,29,179,180,181],"Type 2 Diabetes","Prediabetes \u002F Type 2 Diabetes","Obesity & Overweight","Obesity and Diabetes Mellitus, Type 2",[183,184,185,186,187,188,189,190,191,192,193,194,195,196,28,197,198,199,200,201,202,203,204,205],"Omega-3 fatty acids","EPA","DHA","Low-density lipoproteins","LDL","Overweight","Obesity","Insulin secretion","Insulin sensitivity","LDL size","LDL diameter","Inflammation","White adipose tissue","HyperapoB","Botnia clamp","Intravenous glucose tolerance test","Hyperinsulinemic euglycemic clamp","Adipose tissue needle biopsy","Oral glucose tolerance test","Eicosapentaenoic acid","Docosahexaenoic acid","High plasma apoB","Disposition index","2026-05-08",{"date":208,"type":38},"2026-05-12",{"date":99,"type":22},{"date":211,"type":22},"2029-12",{"name":213,"class":45},"May Faraj, PDt, PhD",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100614988","phase-2-efficacy-and-safety-of-oral-controlled-release-nicotinic-acid-cir-na-for-the-remission-of-prediabetes-concept-100614988","NCT07286747","Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)","A Phase II, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) for Inducing Remission in Subjects With Prediabetes","CONCEPT","Inclusion Criteria:\n\n1. Male and female participants ≥ 18 to \\\u003C 80 years of age (at the time of signing the informed consent).\n2. Body mass index ≥ 20 kg\u002Fm².\n3. Ability to understand and comply with the protocol.\n4. Signed written informed consent.\n5. Diagnosed prediabetes according to the current EASD\u002FDDG guidelines. Prediabetes is present if at least one value is in the prediabetes range, but no value is in the T2DM range.\n6. Subgroup-specific: MASLD fibrosis score ≥ -1.455.\n\nExclusion Criteria:\n\n1. Presence or a history of type 2 diabetes mellitus according to the current EASD\u002FDDG guidelines.\n2. Participants with relevant medical conditions (based on evaluation of medical history and screening assessments), unstable and uncontrolled underlying diseases, e.g., hypothyroidism, asthma, COPD or arterial hypertension, can be excluded per judgment of the Investigator.\n3. Renal impairment (glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73).\n4. Impairment of hepatic function (one or more of liver enzymes alanine transaminase, aspartate transaminase and gamma glutamyl transferase \\[\\> 3-fold compared to normal range\\]).\n5. Current infection with hepatitis B or C.\n6. Clinically relevant abnormal findings in medical history or screening assessments which, in the opinion of the Investigator, may put the participant at risk when participating in the trial or provide difficulties in interpreting the trial data.\n7. Current or history of malignancy except for completely resected basal cell carcinoma and squamous cell carcinoma of the skin.\n8. Alcohol or drug abuse within the last 2 years at the discretion of the Investigator.\n9. Subgroup-specific: Any circumstances which could contradict MRI and MRS imaging. For details, see Informed Consent Form (ICF) for additional examinations.\n10. Regular use of any prescribed or over-the-counter medication, food supplements or herbal preparations, which cannot be terminated 3 weeks before baseline and during the full duration of the trial. Pain medication (e.g., ibuprofen or paracetamol), topical allergy medicines, hormone replacement therapies and oral contraceptives according to label are allowed. Medications in stable doses for controlling stable underlying diseases (see exclusion criterion 2) are also allowed per judgment of the Investigator.\n11. Use of antibiotics (systemic or gut-acting \\[non-absorbed\\]) within 8 weeks prior to the first dose of IMP.\n12. Long term use of higher doses of proton pump inhibitors, targeted H2-receptor antagonists or antacid formulations (i.e., doses equivalent to \\> 40 mg pantoprazole per day).\n13. Known hypersensitivity towards any component of the CIR-NA or placebo tablets.\n14. Participation in a clinical trial (as defined in the clinical trial regulation (CTR)), currently or within 4 weeks prior to screening for this trial or intake of an IMP within the last 8 weeks or 5 half-lives (whichever is longer) prior to screening (or longer, if necessary, at the Investigator's discretion).\n15. Participants under legal supervision or guardianship, including participants who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.\n16. Participants who are dependent on the Investigator or the Sponsor.\n17. Pregnant or breastfeeding women.\n18. Women of childbearing potential (WoCBP) not using highly effective contraception till at least 1 month after last dosing of IMP.\n19. Male participants with female partners of childbearing potential who are not willing to use a highly effective contraception till at least 1 month after last dosing of IMP.\n20. Any other circumstances or medical conditions which could contradict a trial participation and lead the Investigator to assess the participant as unsuitable for trial participation.","79 Years",{"count":224,"type":22},390,[175],"The goal of this clinical trial is to prevent the change from prediabetes (a pre-stage of type 2 diabetes mellitus (T2DM)) to T2DM in participants with prediabetes using oral CIR-NA (a nicotinic acid formulation that is designed to be released after reaching the ileum) which targeted the gut microbiota. The main questions it aims to answer are:\n\n1. Is CIR-NA effective and does it prevent the change from prediabetes to T2DM?\n2. Is the safety of CIR-NA that was observed in the Phase I clinical trial confirmed in subjects with prediabetes?\n\nResearchers will compare CIR-NA to a placebo (a look-alike substance that contains no drug) in terms of an extended safety evaluation including safety laboratory assessments, physical examination, vital signs and 12-lead ECG.\n\nParticipants will:\n\nTake CIR-NA or a placebo every day for 26-weeks. Visit the clinic at week 1 and subsequently once every 4 weeks for checkups and tests.\n\nReceive standardized lifestyle recommendations regarding nutrition and physical activity during the intervention.",[29],"2026-03-26",{"date":230,"type":38},"2026-04-01",{"date":232,"type":38},"2026-03-03",{"date":234,"type":22},"2028-12-31",{"name":236,"class":45},"University Hospital Schleswig-Holstein",2,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":256,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":46},"100598614","probiotic-impact-on-cognitive-performance-and-metabolic-outcomes-in-overweight-young-adults-with-impaired-glucose-regulation-100598614","NCT07073781","Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation","A Double-blind Placebo-controlled Exploratory Trial to Assess the Impact of Daily Lab4P Probiotic Supplementation on Cognitive Performance and Metabolic Regulation in Overweight Young Adults With Impaired Glucose Regulation","ProCog","Inclusion Criteria\n\n* Aged 18-40 years\n* Body Mass Index (BMI) between 25.0 and 29.9 kg\u002Fm² (classified as overweight)\n* In good general health (self-reported)\n* Normal self-reported sleep patterns, with no history of diagnosed sleep disorders\n* Willing and able to provide informed consent\n* Able to comply with study procedures, including fasting and oral glucose tolerance testing\n\nExclusion Criteria:\n\n* Diagnosed diabetes (any type).\n* Diagnosed sleep disorders.\n* Fasting glucose \\>6.9 mmol\u002FL during screening.\n* History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy).\n* Major surgery, significant illness, trauma, infection, or myocardial infarction within the past 6 weeks.\n* Current use of medications affecting glucose metabolism or probiotics\n* Pregnancy or actively trying to conceive\n* Night shift work within the past month",{"count":247,"type":22},70,[25],"This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.",[251,252,29,253,254,255],"Impaired Glucose Regulation","Impaired Glucose Tolerance (Prediabetes)","Overweight (BMI > 25)","Cognitive Dysfunction","Neurovascular Coupling Mechanism and Cognitive Function",[257,258,259,260,261,262],"Probiotic supplementation","Psychobiotic","Cognitive performance","Metabolic function","Impaired glucose tolerance","Gut-brain axis","2026-03-25",{"date":265,"type":38},"2026-03-31",{"date":267,"type":38},"2025-08-15",{"date":269,"type":22},"2026-08-20",{"name":271,"class":45},"Leeds Beckett University",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":292,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":46},"100582737","peanuts-for-cardiometabolic-brain-and-intestinal-health-100582737","NCT06867198","Peanuts for Cardiometabolic, Brain, and Intestinal Health","Impact of Peanuts on Cardiometabolic, Cognitive, and Intestinal Health in Prediabetes Among Racially Diverse Populations","Inclusion Criteria:\n\n* men and women\n* 20-59 years of age\n* BMI: 24.5 - 35.5 kg\u002Fm\\^2\n* Prediabetes (fasting blood glucose levels 100-125 mg\u002FdL and\u002For HbA1c between 5.7-6.4%)\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to peanuts and peanut products\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n\nMRI Exclusion Criteria:\n\n* Certain neurological disorders (e.g., uncontrolled seizure disorders)\n* Braces on their teeth, a cardiac pacemaker; hearing aid; other metal in the body or eyes (which may include certain metallic-embedded tattoos), including but not limited to pins, screws, shrapnel, plates, dentures or other metal objects","20 Years","59 Years",{"count":282,"type":22},72,[25],"The overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.",[28,29,286,287,288,289,290,291],"Cognition","Microvascular Function","Gut Microbiota","Endothelial Function (Reactive Hyperemia)","Arterial Stiffness, Blood Pressure","Adult",[293,294,295,296,297,298,299,300,301,302,303,304,305,306,307],"prediabetes","peanuts","functional foods","nuts","metabolic health","insulin resistance","type II diabetes","microvascular function","dietary intervention","cognitive function","vascular function","neuroimaging","endothelial function","cardiovascular health","gut microbiota","2026-03-23",{"date":310,"type":38},"2026-03-27",{"date":312,"type":38},"2025-03-06",{"date":314,"type":22},"2027-09",{"name":316,"class":45},"Georgia State University",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":324,"minAge":279,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":335,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":46},"100572621","wild-blueberries-for-gut-brain-and-cardiometabolic-health-in-prediabetes-100572621","NCT06735651","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.","Inclusion Criteria:\n\n* Women aged 20-65 years old\n* Prediabetes (fasting blood glucose 100-125 mg\u002FdL and\u002For HbA1c percentage between 5.7-6.4)\n* Body Mass Index between 25-30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, thyroid, stage 1 \\& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n* Currently taking berry supplements or recently participated in another study taking berry supplements","FEMALE","65 Years",{"count":327,"type":22},30,[25],"The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.",[29,331,291,289,332,286,333,288,188,194,287,334],"Female","Arterial Stiffness","Oxidative Stress","Body Composition",[336,28,153,337,338,339,340,341,342,343,344,345,287,346],"Blueberries","Functional foods","Dietary intervention","Endothelial function","Vascular function","Cardiovascular health","Metabolic health","Gut microbiota","Cognitive function","Type II diabetes","Wild Blueberries",{"date":263,"type":38},{"date":349,"type":38},"2024-09-20",{"date":127,"type":22},{"name":316,"class":45},{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":68,"sex":17,"minAge":360,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":46},"100626785","effects-of-akkermansia-muciniphila-and-berberine-supplementation-on-insulin-sensitivity-in-night-shift-workers-100626785","NCT07440147","Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers","Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers: a Double-blind, Randomised, Placebo-controlled, Crossover Study Within the Shift2Health Project","Shift2Health","Inclusion Criteria:\n\n* Health care or industrial shift worker\n* Employed or self-employed working ≥ 24 h\u002Fweek\n* Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights\u002Fmonth\n* Night shift work duration \\> 3 years\n* 4 or more night shifts\u002Fmonth\n\nExclusion Criteria:\n\n* BMI of 40 kg\u002Fm² or higher\n* Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women\n* Bariatric surgery\n* Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study\n* Diagnosed diabetes type 1 or type 2\n* Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH\u002FT4 levels without stable medication for more than 3 months)\n* Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)\n* Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable\n* Regular intake of anticoagulants\n* Known allergy to any inactive or active ingredients in the study products\n* Participation in other clinical intervention trials during the study\n* Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)","21 Years",{"count":362,"type":22},200,[25],"Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.\n\nTogether, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.\n\nBased on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.\n\nAssessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.\n\nThe primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.\n\nThese measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.",[180,366,367,29],"Circadian Rhythm Disorders","Gut Microbiota Modulation","2026-02-23",{"date":370,"type":38},"2026-02-27",{"date":372,"type":38},"2026-01-20",{"date":374,"type":22},"2028-02",{"name":376,"class":377},"FH Joanneum Gesellschaft mbH","INDUSTRY",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":68,"sex":17,"minAge":18,"maxAge":325,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":46},"100622154","evaluating-a-liquid-extract-of-carob-to-improve-blood-sugar-in-people-with-prediabetes-100622154","NCT07379931","Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes","Randomized Clinical Trial to Analyze the Efficacy of a Liquid Carob Extract on the Glucose Metabolism of Subjects With Prediabetes.","GLIA","Inclusion Criteria:\n\n* Subjects of both sexes aged between 18 and 65.\n* Diagnosis of prediabetes according to the American Diabetes Association (at least one of the following criteria):\n* Impaired fasting glucose (100-125 mg\u002FdL)\n* Glucose intolerance (oral glucose tolerance test with blood glucose between 140-199 mg\u002FdL after 2 hours).\n* Glycated hemoglobin between 5.7 and 6.4%\n* Subjects with a body mass index between 20-35 kg\u002Fm2.\n* Stable eating habits: no weight gain or loss of more than 5 kg in the last ten weeks.\n* Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements.\n\nExclusion Criteria:\n\n* Use of medications that may interfere with glucose metabolism.\n* Subjects with a history of any type of liver or kidney disease.\n* Alcohol consumption greater than 20 g\u002Fday.\n* History of allergic hypersensitivity or poor tolerance to any component of the products under study.\n* Participation in another clinical trial in the three months prior to the study.\n* Unwillingness or inability to comply with clinical trial procedures.\n* Pregnant or breastfeeding women.",{"count":247,"type":22},[25],"This study evaluates whether a liquid carob extract can improve blood glucose levels in individuals with prediabetes. Participants are selected according to predefined health criteria and randomly assigned to two groups: one group receives the carob extract and the other receives an inert liquid (placebo). Blood samples are collected and glucose-related parameters are measured throughout the study to assess changes over time. The objective is to determine whether this extract may contribute to better glycemic control and help prevent progression to diabetes.",[29],[28,391,392,393],"Glucose","Carob","Placebo","2026-01-23",{"date":396,"type":38},"2026-02-02",{"date":398,"type":22},"2026-01-01",{"date":400,"type":22},"2026-04-30",{"name":402,"class":45},"Universidad Católica San Antonio de Murcia",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":17,"minAge":279,"maxAge":69,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":420,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":46},"100571717","antidiabetic-effect-of-olive-pomace-oil-100571717","NCT06723886","Antidiabetic Effect of Olive Pomace Oil","Assessment of the Potential Antidiabetic Effects of Olive Pomace Oil in Diabetic or Prediabetic Subjects: Postprandial Study and Chronic Intervention","OPODIABE","Inclusion Criteria:\n\n* Fasting blood glucose between 100-126 mg\u002FdL and\u002For\n* Glycated haemoglobin (HbA1c) between 5.7-6.4% and\u002For\n* Diabetic persons with Fasting blood glucose \\>126 mg\u002FdL and\u002For\n* Diabetic persons with Glycated haemoglobin (HbA1c) \\> 6.4%\n\nExclusion Criteria:\n\n* Kidney or liver diseases\n* Gastrointestinal diseases (irritable bowel syndrome, Crohn disease, chronic bowel inflammation)\n* Food allergies\u002Fintolerances\n* Vegetarians\u002Fvegans\n* Smoking\n* Pregnant or lactating women\n* On prescription drugs other than for hypertension\u002Fthyroid\u002Fdyslipidemia\u002Fglucose control, or changes in dosage in the last 3 months\n* Consumption of vitamins, dietary supplements or nutraceuticals",{"count":412,"type":22},50,[25],"This clinical trial aims at assessing whether consumption of olive pomace oil in the diet may benefit persons with type 2 diabetes mellitus or persons at risk of developing the disease (prediabetic persons).\n\nThe main questions the study aims to answer are:\n\n* May olive pomace oil prevent a high increase of blood glucose levels when consumed in a meal together with carbohydrates in diabetic\u002Fprediabetic patients?\n* May olive pomace oil decrease fasting blood glucose levels of diabetic\u002Fprediabetic patients after consuming it daily?\n* May daily consumption of olive pomace oil improve glucose homeostasis and other alterations like elevated blood lipids or inflammation, which also affect persons with diabetes or prediabetes?\n\nResearchers will compare the effect of consuming olive pomace oil to the effects of a comparison oil (high-oleic acid sunflower oil).\n\nParticipants will:\n\nIn different days, they will consume white bread alone or the oils (olive pomace oil, high-oleic acid sunflower oil or extra virgin olive oil) spread on white bread and blood will be collected at different times during 2 h. This study to observe the increase of blood glucose after a carbohydrate-rich breakfast will be part of the so-called \"postprandial\" study, and will be conducted during 3 weeks, during which participants will consume corn oil on a daily basis.\n\nParticipants will also take part in the \"chronic\" study, that will last 22 weeks in total. During this study, they will firstly \"wash\" the effects of the oil they normally consume in their diets by consuming corn oil during 3 weeks. It is during these weeks when they will attend the Human Nutrition Unit (HNU) of ICTAN to carry on the \"postprandial\" study described in the previous paragraph.\n\nAfter the initial 3 weeks, participants will consume olive pomace oil as the only oil in their diets during 8 weeks, \"wash\" its effects again by consuming corn oil during 3 weeks and then change to consume the other oil (high-oleic acid sunflower oil) during 8 weeks.\n\nDuring the chronic study, they will visit the clinic once every 4 weeks for checkups and tests. They will refrain from eating other oils or specific fat-rich foods. Participants will also attend our phone calls to ask them what they ate the day before on different weeks during the study, and wear an accelerometer during 1 week to record their physical activity. They will keep a diary of the doses of insulin\u002Fmetformin used and the blood glucose levels they measured at home.",[416,29,417,418,419],"Type 2 Diabetes Mellitus","Prediabetic State","Diabetes","Diabetes Mellitus",[421,418,28,422,423,424,425],"Olive pomace oil","Antidiabetic effect","Postprandial study","Chronic intervention","High-oleic acid sunflower oil","2024-12-06",{"date":428,"type":38},"2024-12-11",{"date":430,"type":22},"2025-01-15",{"date":432,"type":22},"2026-06-30",{"name":434,"class":435},"Instituto de Ciencia y Tecnología de Alimentos y Nutrición","OTHER_GOV"]